BellBrook Labs receives grant to develop drugs for lupus
Industry News: BellBrook Labs receive NIH grant to treat lupus and related autoimmune diseases The grant will be used to accelerate the discovery of new treatments for autoimmune diseases by targeting the cGAS-STING pathway 22 Apr 2021 BellBrook Labs has been awarded a $1.8 million Phase II SBIR grant by the National Institute of Allergy and Infectious Diseases (NIAID) to develop lead molecules that block cyclic GAMP synthase (cGAS) for the treatment of lupus and other autoimmune diseases. BellBrook’s CEO, Dr. Robert Lowery is the principal investigator for the effort, and Dr. Keith Elkon...